House Dust Mite Disease (HDMD) Market Expected to Witness Steady Growth Through 2036, Driven by Rising Allergy Burden and Expanding Allergen Immunotherapy Pipeline | DelveInsight

The House Dust Mite Disease (HDMD) market is expected to witness steady growth across the Seven Major Markets (7MM) during the forecast period (2022-2036). Market expansion is anticipated to be driven by the increasing prevalence of allergic rhinitis, asthma, and atopic dermatitis associated with house dust mite sensitization, growing disease awareness, improved diagnostic practices, and the anticipated launch of emerging allergen immunotherapies. Advancements in disease-modifying treatments and expanding adoption of allergen immunotherapy are expected to reshape the HDMD treatment landscape over the coming years.

DelveInsight's "House Dust Mite Disease (HDMD) Market Insights, Epidemiology, and Market Forecast-2036" report provides a comprehensive assessment of disease epidemiology, current treatment practices, emerging therapies, market trends, pricing analysis, therapy uptake, reimbursement landscape, and market forecasts across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report further evaluates patient burden, competitive intelligence, key opinion leader perspectives, and commercial opportunities expected to shape the HDMD market through 2036.

The report also delivers detailed insights into historical and forecasted market performance, epidemiological trends, treatment algorithms, unmet needs, SWOT analysis, pricing dynamics, and the evolving competitive landscape to support strategic decision-making for stakeholders operating in the allergy and immunology sectors.

To know more about the House Dust Mite Disease (HDMD) market, epidemiology, and forecast, Click here:
https://www.delveinsight.com/sample-request/house-dust-mite-allergy-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Key Takeaways from the House Dust Mite Disease (HDMD) Market Report

• The House Dust Mite Disease (HDMD) market is expected to expand steadily across the 7MM during the forecast period (2022-2036), supported by increasing diagnosed patient populations, broader use of allergen immunotherapy, and anticipated launches of emerging disease-modifying therapies.
• House dust mite allergy is highly prevalent worldwide and is strongly associated with allergic rhinitis, asthma, and atopic dermatitis, contributing substantially to the overall allergic disease burden. The major allergenic species include Dermatophagoides pteronyssinus, Dermatophagoides farinae, and Euroglyphus maynei, with the first two accounting for the majority of sensitization cases globally.
• According to DelveInsight estimates, the United States accounted for nearly 28 million diagnosed prevalent cases of HDMD in 2025, with patient numbers expected to increase through 2036 owing to climate change, environmental shifts, and aging-related immune alterations.
• The US HDMD market was valued at approximately USD 3 billion in 2025 and is projected to expand steadily during the forecast period as uptake of allergen immunotherapies continues to increase.
• Currently, ODACTRA (US)/ACARIZAX (EU)/MITICURE (Japan) and ACTAIR/ORYLMYTE/AITMYTE represent the principal approved disease-modifying sublingual immunotherapies (SLIT) for house dust mite allergy, while additional pipeline therapies are expected to strengthen the future treatment landscape.
• The emerging pipeline includes promising candidates such as PURETHAL Mites (HAL Allergy), BELTAVAC (Probelte Pharma), MM09 (Inmunotek), and Tregalizumab (T-Balance Therapeutics), several of which are progressing through Phase III clinical development.

Key Factors Driving the House Dust Mite Disease (HDMD) Market

Growing Burden of Allergic Diseases
The rising prevalence of allergic rhinitis, allergic asthma, and atopic dermatitis continues to expand the number of patients sensitized to house dust mites, increasing demand for effective long-term treatment strategies beyond symptomatic management.

Expansion of Allergen Immunotherapy
Increasing adoption of allergen immunotherapy (AIT), including both subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT), is driving market growth by offering disease-modifying benefits that extend beyond symptomatic relief.

Advancing Late-stage Pipeline
Several investigational immunotherapies, including MM09, PURETHAL Mites, BELTAVAC, and Tregalizumab, are progressing through mid-to-late-stage clinical development and are expected to expand treatment options across the 7MM.

Improved Diagnosis and Disease Awareness
Advances in diagnostic testing, increased physician awareness, and greater recognition of allergen-specific sensitization are supporting earlier diagnosis and expanding the addressable patient population for disease-modifying therapies.

House Dust Mite Disease (HDMD) Market Analysis

House Dust Mite Disease remains one of the leading causes of perennial allergic disorders worldwide, affecting millions of individuals through chronic allergic rhinitis, asthma, and atopic dermatitis. Current treatment relies heavily on antihistamines, intranasal corticosteroids, leukotriene receptor antagonists, decongestants, and allergen immunotherapy. While conventional pharmacologic therapies provide symptomatic relief, allergen immunotherapy remains the only disease-modifying treatment capable of inducing long-term immune tolerance. According to DelveInsight, increasing prevalence of allergic diseases, expanding adoption of allergen immunotherapy, growing physician awareness, and continued advancement of late-stage pipeline therapies are expected to support sustained growth of the HDMD market across the Seven Major Markets through 2036.

Get a Free sample for the House Dust Mite Disease (HDMD) Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/sample-request/house-dust-mite-allergy-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

House Dust Mite Disease (HDMD) Competitive Landscape

The House Dust Mite Disease (HDMD) therapeutic landscape is evolving with the continued expansion of allergen immunotherapy (AIT) and the development of next-generation disease-modifying therapies. While antihistamines, intranasal corticosteroids, leukotriene receptor antagonists, and decongestants remain the mainstay of symptomatic management, allergen immunotherapy represents the only treatment approach capable of inducing long-term immune tolerance. Currently, ODACTRA (US)/ACARIZAX (EU)/MITICURE (Japan) and ACTAIR/ORYLMYTE/AITMYTE are the principal approved sublingual immunotherapies (SLIT), while several late-stage pipeline candidates are expected to further strengthen the future treatment landscape.

Leading companies advancing therapies for HDMD include ALK-Abelló, Stallergenes Greer, HAL Allergy, Inmunotek, Probelte Pharma, T-Balance Therapeutics, and LETI Pharma, among others.

ODACTRA/ACARIZAX/MITICURE: ALK-Abelló
ODACTRA (marketed as ACARIZAX in Europe and MITICURE in Japan) is a house dust mite allergen extract sublingual immunotherapy (SLIT) tablet indicated for patients with HDM-induced allergic rhinitis, with or without conjunctivitis, in individuals aged 5-65 years. The therapy contains standardized extracts of Dermatophagoides farinae and Dermatophagoides pteronyssinus and functions by inducing long-term immune tolerance through repeated allergen exposure. In February 2025, the US FDA approved ODACTRA for children aged 5-11 years, expanding its previous indication beyond patients aged 12-65 years. ODACTRA currently represents the most broadly approved disease-modifying therapy for HDMD across the 7MM.

House Dust Mite Allergy Vaccine (PURETHAL Mites): HAL Allergy
PURETHAL Mites is a subcutaneous allergen immunotherapy (SCIT) developed by HAL Allergy using chemically modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae adsorbed to aluminum hydroxide. The therapy is currently undergoing Phase III clinical development for house dust mite allergy. Although other PURETHAL products are marketed in several European countries for pollen and grass allergies, PURETHAL Mites has not yet received marketing authorization for HDM allergy.

MM09: Inmunotek
MM09 is an investigational polymerized allergoid coupled to mannan developed by Inmunotek. The therapy is currently in Phase III clinical development for patients with mild-to-moderate asthma and allergic rhinitis/rhinoconjunctivitis associated with Dermatophagoides pteronyssinus and/or Dermatophagoides farinae sensitization. The ongoing study is evaluating the efficacy and safety of subcutaneous immunotherapy and represents one of the most advanced pipeline assets in the HDMD market.

BELTAVAC: Probelte Pharma
BELTAVAC is a polymerized allergen extract mixture containing Dermatophagoides pteronyssinus and Dermatophagoides farinae, developed by Probelte Pharma. The therapy has been manufactured and distributed in Europe for nearly two decades and is currently undergoing a Phase III clinical trial to generate robust long-term efficacy and safety data in patients with moderate-to-severe allergic rhinitis/rhinoconjunctivitis, with or without controlled asthma.

Tregalizumab: T-Balance Therapeutics
Tregalizumab is an investigational anti-CD4 immunomodulatory therapy being developed by T-Balance Therapeutics. The therapy is currently in Phase II clinical development and is expected to expand future treatment options for HDMD through immune regulation beyond conventional allergen immunotherapy.

Discover more about therapies expected to transform the House Dust Mite Disease (HDMD) market @ House Dust Mite Disease (HDMD) Treatment Landscape

Recent Developments in the House Dust Mite Disease (HDMD) Market

• In February 2025, the US FDA approved ODACTRA for treating house dust mite-induced allergic rhinitis in children aged 5-11 years, expanding its previous indication.
• In January 2025, the National Institute for Health and Care Excellence (NICE) recommended ACARIZAX for persistent moderate-to-severe house dust mite allergic rhinitis in adults and adolescents.
• In December 2024, European regulators approved the expansion of ACARIZAX to children aged 5-11 years across 21 EU countries through a Type II variation procedure.
• LETI Pharma is conducting a Phase III clinical trial in Spain evaluating a subcutaneous immunotherapy formulation containing Dermatophagoides pteronyssinus and Dermatophagoides farinae allergenic extracts in pediatric and adult patients with moderate-to-severe allergic rhinoconjunctivitis, with or without controlled asthma.
• Several investigational therapies, including PURETHAL Mites, MM09, BELTAVAC, and Tregalizumab, continue advancing through clinical development and are expected to reshape the future HDMD treatment landscape.

What is House Dust Mite Disease (HDMD)?

House Dust Mite Disease (HDMD) is an IgE-mediated allergic disorder triggered by sensitization to allergens produced by house dust mites, particularly Dermatophagoides pteronyssinus and Dermatophagoides farinae. The disease is strongly associated with allergic rhinitis, allergic asthma, and atopic dermatitis, producing symptoms such as sneezing, rhinorrhea, nasal congestion, itching, conjunctivitis, wheezing, and impaired quality of life. Current management includes environmental allergen avoidance, symptomatic pharmacologic therapies, and allergen immunotherapy, which remains the only disease-modifying treatment capable of inducing sustained immune tolerance.

House Dust Mite Disease (HDMD) Epidemiology Segmentation

The DelveInsight report provides a comprehensive epidemiological assessment of House Dust Mite Disease across the Seven Major Markets (7MM) during 2022-2036, segmented into:
• Total Prevalent Cases of House Dust Mite Allergy
• Total Diagnosed Prevalent Cases of House Dust Mite Allergy
• Gender-specific Diagnosed Prevalent Cases
• Allergen-specific Diagnosed Prevalent Cases
• Total Treated Cases
• Country-specific epidemiology across the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.

Download the report to explore detailed epidemiology trends, emerging therapies, competitive intelligence, and commercial opportunities in the House Dust Mite Disease (HDMD) market:
https://www.delveinsight.com/sample-request/house-dust-mite-allergy-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the House Dust Mite Disease (HDMD) Market Report

• Study Period: 2022-2036
• Coverage: Seven Major Markets (7MM) - United States, Germany, France, Italy, Spain, the United Kingdom, and Japan
• Key Companies: ALK-Abelló, Stallergenes Greer, HAL Allergy, Inmunotek, Probelte Pharma, T-Balance Therapeutics, LETI Pharma, and others
• Current Treatment Landscape: Antihistamines, intranasal corticosteroids, leukotriene receptor antagonists, decongestants, allergen immunotherapy (SLIT and SCIT), and supportive care
• Emerging Therapies: PURETHAL Mites, BELTAVAC, MM09, Tregalizumab, and additional investigational allergen immunotherapies
• Epidemiology Segmentation: Total prevalent cases, diagnosed prevalent cases, gender-specific cases, allergen-specific cases, and treated cases across the 7MM
• Market Insights: Historical and forecasted market size, therapy uptake, pricing trends, analogue assessment, competitive landscape, unmet needs, SWOT analysis, and market forecasts through 2036
• Market Access: Country-specific reimbursement and Health Technology Assessment (HTA) landscape across the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan
• Additional Coverage: Patient journey, Key Opinion Leader (KOL) perspectives, therapy launch assessment, reimbursement dynamics, market access strategies, and analyst views.

To learn more about the House Dust Mite Disease (HDMD) market, epidemiology, and emerging treatment landscape, visit:
https://www.delveinsight.com/sample-request/house-dust-mite-allergy-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

• House Dust Mite Disease (HDMD) Market Report Introduction
• House Dust Mite Disease (HDMD) Market Executive Summary
• House Dust Mite Disease (HDMD) Market Overview at a Glance
• House Dust Mite Disease (HDMD) Disease Background and Overview
• House Dust Mite Disease (HDMD) Treatment Guidelines
• House Dust Mite Disease (HDMD) Epidemiology and Market Forecast Methodology
• House Dust Mite Disease (HDMD) Epidemiology Analysis
• House Dust Mite Disease (HDMD) Patient Population Analysis
• House Dust Mite Disease (HDMD) Patient Journey
• House Dust Mite Disease (HDMD) Marketed Drugs
• House Dust Mite Disease (HDMD) Emerging Drugs
• House Dust Mite Disease (HDMD) Emerging Therapy Assessment
• House Dust Mite Disease (HDMD) Market Size Analysis (2022-2036)
• House Dust Mite Disease (HDMD) Market Size by Therapies
• House Dust Mite Disease (HDMD) Drug Uptake Analysis
• House Dust Mite Disease (HDMD) Competitive Landscape
• House Dust Mite Disease (HDMD) Key Companies
• House Dust Mite Disease (HDMD) Key Therapies
• House Dust Mite Disease (HDMD) Conjoint Analysis
• House Dust Mite Disease (HDMD) Key Market Forecast Assumptions
• House Dust Mite Disease (HDMD) Unmet Needs
• House Dust Mite Disease (HDMD) SWOT Analysis
• House Dust Mite Disease (HDMD) Key Opinion Leader (KOL) Views
• House Dust Mite Disease (HDMD) Market Access and Reimbursement
• Analyst Views
• Appendix

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +1-469-945-7679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.